Our Science
Cutting Edge Science and Innovation
As a clinical stage immunotherapeutics company, Aqualung Therapeutics is providing breakthrough drugs to address multiple unmet needs in diseases characterized by runaway inflammation and unremitting vascular leak
Our Platform
Aqualung has developing and continues to develop novel immunotherapeutics designed to address serious unmet therapeutic needs across the globe. Our platform consists of a humanized monoclonal antibody (ALT-100 mAb), a novel nanocarrier (NTyP-100) and a fusion immunoglobulin protein (SELP-100)
Discovery of eNAMPT as a therapeutic target in inflammatory and fibrotic disease.
The seminal scientific discovery underlying the Aqualung Therapeutics portfolio made when Dr. Garcia (CEO) was Chief of Pulmonary and Critical Care Medicine at Johns Hopkins University School of Medicine. The Garcia laboratory advanced a functional genomic research program designed to identify novel candidate genes involved in contributing to the morbidity and mortality of serious inflammatory and fibrotic disorders such as ARDS, pulmonary fibrosis and pulmonary hypertension (see Figures below) and identified nicotinamide phosphoribosyltransferase (NAMPT) as a highly novel candidate gene in a number of inflammatory and fibrotic diseases.
Of critical importance, Aqualung Therapeutics has now developed a a “First in Man” immune-based humanized monoclonal antibody (mAb), ALT-100, to inhibit eNAMPT binding to TLR4 (see Figure below). The ALT-100 mAb is designed to prevent the development of “unchecked inflammation” and progressive fibrosis in a number of severe inflammatory diseases, thereby addressing important medical and societal unmet needs. ALT-100 is a novel and potential game-changing therapy for many inflammatory conditions such as Acute Respiratory Distress Syndrome, Ventilator Induced Lung Injury, Radiation Induced Lung Injury, Chorioamnionitis, Prostate Cancer, Pulmonary Hypertension and Pulmonary Fibrosis..
